UCTD
MCID: UND007
MIFTS: 30

Undifferentiated Connective Tissue Disease (UCTD) malady

Categories: Rare diseases, Bone diseases

Aliases & Classifications for Undifferentiated Connective Tissue Disease

Aliases & Descriptions for Undifferentiated Connective Tissue Disease:

Name: Undifferentiated Connective Tissue Disease 50 69
Undifferentiated Connective Tissue Syndrome 50 56
Uctd 50 56

Classifications:



External Ids:

Orphanet 56 ORPHA90002
UMLS via Orphanet 70 C0409999
ICD10 via Orphanet 34 M35.8

Summaries for Undifferentiated Connective Tissue Disease

NIH Rare Diseases : 50 undifferentiated connective tissue disease is a condition that affects the joints and muscles of the body. a disorder is classified as undifferentiated connective tissue disease when it cannot be classified as another type of connective tissue disease, such as rheumatoid arthritis or lupus. symptoms of undifferentiated connective tissue disease may vary but include constriction of the blood vessels in the hands and feet, especially in response to cold (raynaud phenomenon), sensitivity to light, joint pain (arthralgia), muscle weakness, and dryness in the eyes and mouth. undifferentiated connective tissue disease is most likely to occur in caucasian women in their 40s-60s. undifferentiated connective tissue disease is a type of autoimmune disease. this means that the system of the body that is responsible for protection from infection (immune system) is attacking the body itself. the cause of most autoimmune diseases is unknown, but is thought to include both environmental and genetic factors. diagnosis of undifferentiated connective tissue disease can be obtained through blood tests and imaging (ct scan) of the chest. treatment includes non-steroidal anti-inflammatory drugs (nsaids) and avoiding exposure to extreme temperatures.  last updated: 10/31/2016

MalaCards based summary : Undifferentiated Connective Tissue Disease, also known as undifferentiated connective tissue syndrome, is related to connective tissue disease and pneumonia. An important gene associated with Undifferentiated Connective Tissue Disease is SSB (Sjogren Syndrome Antigen B). The drugs Methotrexate and Etanercept have been mentioned in the context of this disorder. Affiliated tissues include testes, eye and lung.

Wikipedia : 71 Undifferentiated connective tissue disease (UCTD) is a disease in which the body mistakenly attacks its... more...

Related Diseases for Undifferentiated Connective Tissue Disease

Diseases related to Undifferentiated Connective Tissue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 30)
id Related Disease Score Top Affiliating Genes
1 connective tissue disease 10.7
2 pneumonia 10.1
3 interstitial lung disease 10.1
4 lung disease 10.1
5 systemic lupus erythematosus 10.0
6 lupus erythematosus 10.0
7 rheumatic disease 9.9
8 endotheliitis 9.9
9 nonspecific interstitial pneumonia 9.9
10 hepatitis 9.9
11 primary biliary cirrhosis 9.9
12 protein-losing enteropathy 9.9
13 vasculitis 9.9
14 antisynthetase syndrome 9.7
15 calcinosis 9.7
16 lymphocytic vasculitis 9.7
17 dermatitis 9.7
18 superior vena cava syndrome 9.7
19 idiopathic interstitial pneumonia 9.7
20 mixed connective tissue disease 9.7
21 hepatitis b 9.7
22 myositis 9.7
23 neuromyelitis optica 9.7
24 thyroiditis 9.7
25 pulmonary fibrosis 9.7
26 lipodystrophy 9.7
27 lambert-eaton myasthenic syndrome 9.7
28 localized scleroderma 9.7
29 cardiac tamponade 9.7
30 scleritis 9.7

Graphical network of the top 20 diseases related to Undifferentiated Connective Tissue Disease:



Diseases related to Undifferentiated Connective Tissue Disease

Symptoms & Phenotypes for Undifferentiated Connective Tissue Disease

Drugs & Therapeutics for Undifferentiated Connective Tissue Disease

Drugs for Undifferentiated Connective Tissue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
2
Etanercept Approved, Investigational Phase 4 185243-69-0
3
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 23214-92-8 31703
4
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2 2068-78-2, 57-22-7 5978
5
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
6
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
9
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
11
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-75-2 4033
12
Epirubicin Approved Phase 4,Phase 3 56420-45-2 41867
13
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
14
leucovorin Approved, Nutraceutical Phase 4 58-05-9 54575, 6560146 143
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
16
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3,Phase 1 31703
17
Pirarubicin Investigational Phase 4 72496-41-4
18 Analgesics Phase 4
19 Folic Acid Antagonists Phase 4
20 Gastrointestinal Agents Phase 4
21 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
22 Analgesics, Non-Narcotic Phase 4
23 Dermatologic Agents Phase 4,Phase 2,Phase 1
24 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
25 Vitamin B Complex Phase 4
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Inflammatory Agents Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
34 Hormone Antagonists Phase 4,Phase 2
35 Hormones Phase 4,Phase 2
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
37 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1
39 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
40 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Hormonal Phase 4,Phase 2
43 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
44 Dexamethasone acetate Phase 4,Phase 2 1177-87-3
45 glucocorticoids Phase 4
46 Dexamethasone 21-phosphate Phase 4,Phase 2
47 Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1
48 BB 1101 Phase 4,Phase 2
49 Folate Nutraceutical Phase 4
50 Vitamin B9 Nutraceutical Phase 4

Interventional clinical trials:

(show top 50) (show all 87)
id Name Status NCT ID Phase
1 Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) Unknown status NCT01303874 Phase 4
2 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
3 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Recruiting NCT01746992 Phase 4
4 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4
5 A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs Completed NCT00996606 Phase 3
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
7 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00002995 Phase 3
8 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3
9 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
10 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
11 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
12 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
13 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3
14 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3
15 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3
16 Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients Completed NCT00124449 Phase 2
17 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2
18 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
19 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2
20 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
21 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2
22 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2
23 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2
24 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2
25 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2
26 Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect Completed NCT00003425 Phase 1, Phase 2
27 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2
28 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
29 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2
30 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2
31 Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2
32 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
33 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2
34 CREATE: Cross-tumoral Phase 2 With Crizotinib Recruiting NCT01524926 Phase 2
35 IRCI Gynae Sarcomas, High Grade Uterine Sarcoma Recruiting NCT01979393 Phase 2
36 Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial Recruiting NCT02406781 Phase 2
37 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting NCT02568267 Phase 2
38 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2
39 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2
40 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2
41 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
42 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2
43 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Not yet recruiting NCT03123276 Phase 1, Phase 2
44 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2
45 Sunitinib in Treating Patients With Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2
46 A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis Withdrawn NCT01918904 Phase 2
47 Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis Unknown status NCT00230204 Phase 1
48 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1
49 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1
50 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction Completed NCT00025415 Phase 1

Search NIH Clinical Center for Undifferentiated Connective Tissue Disease

Genetic Tests for Undifferentiated Connective Tissue Disease

Anatomical Context for Undifferentiated Connective Tissue Disease

MalaCards organs/tissues related to Undifferentiated Connective Tissue Disease:

39
Testes, Eye, Lung, Bone, Endothelial, T Cells, Heart

Publications for Undifferentiated Connective Tissue Disease

Articles related to Undifferentiated Connective Tissue Disease:

(show top 50) (show all 75)
id Title Authors Year
1
Undifferentiated connective tissue disease and interstitial lung disease: Trying to define patterns. ( 27979657 )
2016
2
Undifferentiated Connective Tissue Disease, Mixed Connective Tissue Disease, and Overlap Syndromes in Rheumatology. ( 27311225 )
2016
3
CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc). ( 27650429 )
2016
4
Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: analysis of a large monocentric cohort with a long-term follow-up. ( 27703051 )
2016
5
The clinical impact of Anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. ( 27427300 )
2016
6
High prevalence of gluten sensitivity in a cohort of patients with undifferentiated connective tissue disease. ( 25781195 )
2015
7
Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc). ( 25461837 )
2015
8
Case Report and Literature Review: Quinacrine-induced Cholestatic Hepatitis in Undifferentiated Connective Tissue Disease. ( 26136554 )
2015
9
Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature. ( 26384526 )
2015
10
Broader criteria of undifferentiated connective tissue disease in idiopathic interstitial pneumonias. ( 25682542 )
2015
11
Mechanic's hands in a woman with undifferentiated connective tissue disease and interstitial lung disease - anti-PL7 positive antisynthetase syndrome: a case report. ( 25888844 )
2015
12
Recurrent epistaxis revealing a non-catheter-related superior vena cava syndrome in a hemodialysis patient: Unmasking undifferentiated connective tissue disease. ( 24434394 )
2014
13
Vocal fold bamboo nodes in undifferentiated connective tissue disease. ( 25118316 )
2014
14
Impaired endothelial function in patients with undifferentiated connective tissue disease: a follow-up study. ( 24917564 )
2014
15
Interstitial Pneumonia Related to Undifferentiated Connective Tissue Disease: Pathologic Pattern and Prognosis. ( 25211168 )
2014
16
Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review. ( 25274451 )
2014
17
Increased expression of vascular endothelial growth factor in a case of protein-losing enteropathy with undifferentiated connective tissue disease. ( 24899168 )
2014
18
Hepatitis B vaccination and undifferentiated connective tissue disease: another brick in the wall of the autoimmune/inflammatory syndrome induced by adjuvants (Asia). ( 23884184 )
2013
19
Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders. ( 23974054 )
2013
20
Intrapleural corticosteroid injection in eosinophilic pleural effusion associated with undifferentiated connective tissue disease. ( 24265645 )
2013
21
Capillaroscopic pattern in systemic lupus erythematosus and undifferentiated connective tissue disease: what we still have to learn? ( 22527142 )
2013
22
Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year. ( 22116525 )
2013
23
Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. ( 23442975 )
2013
24
Comparison of characteristics of connective tissue disease-associated interstitial lung diseases, undifferentiated connective tissue disease-associated interstitial lung diseases, and idiopathic pulmonary fibrosis in Chinese Han population: a retrospective study. ( 24171031 )
2013
25
Recurrent orbital myositis in undifferentiated connective tissue disease. ( 22840478 )
2013
26
Conductor of regulatory cells: does vitamin D restore the shifted balance of the distinct regulatory cell types in undifferentiated connective tissue disease? ( 23500533 )
2013
27
Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease. ( 23818915 )
2013
28
Acute fibrinous and organizing pneumonia and undifferentiated connective tissue disease: a case report. ( 22957292 )
2012
29
An unusual case of undifferentiated connective tissue disease presenting as cardiac tamponade. ( 20013265 )
2012
30
Pregnancy in patients with undifferentiated connective tissue disease: a prospective case-control study. ( 21813586 )
2011
31
Undifferentiated connective tissue disease presenting with prevalent interstitial lung disease: case report and review of literature. ( 21645423 )
2011
32
Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease. ( 20868777 )
2011
33
Undifferentiated connective tissue disease with pulmonary involvement. ( 21751630 )
2011
34
A case of hypertrophic cranial pachymeningitis presenting with scleritis in a patient with undifferentiated connective tissue disease. ( 20514324 )
2010
35
Undifferentiated connective tissue disease - an unsolved problem:revision of literature and case studies. ( 20378013 )
2010
36
Late onset of pANCA renal and pulmonary vasculitis in a girl affected by undifferentiated connective tissue disease. ( 20133348 )
2010
37
Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. ( 20069430 )
2010
38
Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD). ( 20483576 )
2010
39
Impaired regulatory T-cell homeostasis due to vitamin D deficiency in undifferentiated connective tissue disease. ( 20615161 )
2010
40
Neonatal lupus in triplet pregnancy of a patient with undifferentiated connective tissue disease evolving to systemic lupus erythematosus. ( 19276307 )
2009
41
Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. ( 19390908 )
2009
42
The diagnostic accuracy of power Doppler ultrasonography for differentiating secondary from primary Raynaud's phenomenon in undifferentiated connective tissue disease. ( 18246378 )
2008
43
Isotype switching and titer variation of anti-Ro/SSA antibodies over time in 100 patients with undifferentiated connective tissue disease (UCTD). ( 18328157 )
2008
44
The effect of newly diagnosed undifferentiated connective tissue disease on pregnancy outcome. ( 18667193 )
2008
45
Vitamin D deficiency in undifferentiated connective tissue disease. ( 18928561 )
2008
46
A case of undifferentiated connective tissue disease: is it a distinct clinical entity? ( 18414458 )
2008
47
Vitamin D or hormone D deficiency in autoimmune rheumatic diseases, including undifferentiated connective tissue disease. ( 19090978 )
2008
48
Anti-thyroid autoantibody-associated interface dermatitis in individuals with undifferentiated connective tissue disease--an unrecognized subset of autoimmune disease? ( 17183617 )
2007
49
Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? ( 17556720 )
2007
50
Open-label study of clarithromycin in patients with undifferentiated connective tissue disease. ( 17023256 )
2006

Variations for Undifferentiated Connective Tissue Disease

Expression for Undifferentiated Connective Tissue Disease

Search GEO for disease gene expression data for Undifferentiated Connective Tissue Disease.

Pathways for Undifferentiated Connective Tissue Disease

GO Terms for Undifferentiated Connective Tissue Disease

Sources for Undifferentiated Connective Tissue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....